Wednesday, June 3, 2026Aggregating 2,418 sources · Updated 38 seconds agoNYC 54° · LON 47° · TOK 61°
Front PageTechFORBES
Tech

Co-Pays For GLP-1 Weight Loss Drugs To Rise If They’re Even Covered

FORBES·May 24 ago·3 min read
Photograph via Forbes
RSS SUMMARY · AGGREGATED FROM FORBES

GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

GLP-1 weight loss drugs like Ozempic, Zepbound and Wegovy are the biggest contributor to rising prescription spending. And that will trigger co-payments to rise.

Continue Reading

The full story continues on Forbes.

Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.